Reviewed by Michael Gill, B. Sc.
11 Essential Thrombocythemia Clinical Trials Near Me
Top Hospitals for Essential Thrombocythemia Clinical Trials
Image of University of Michigan in Michigan.
University of Michigan
Ann Arbor
3Active Trials
9All Time Trials for Essential Thrombocythemia
2011First Essential Thrombocythemia Trial
Image of The University of Texas MD Anderson Cancer Center in Texas.
The University of Texas MD Anderson Cancer Center
Houston
2Active Trials
6All Time Trials for Essential Thrombocythemia
2017First Essential Thrombocythemia Trial
Top Cities for Essential Thrombocythemia Clinical Trials
Image of New York in New York.
New York
6Active Trials
Icahn School of Medicine at Mount SinaiTop Active Site
Image of Ann Arbor in Michigan.
Ann Arbor
5Active Trials
University of MichiganTop Active Site
Essential Thrombocythemia Clinical Trials by Phase of Trial
Phase < 1 Essential Thrombocythemia Clinical Trials
1Active Essential Thrombocythemia Clinical Trials
1Number of Unique Treatments
2Number of Active Locations
Essential Thrombocythemia Clinical Trials by Age Group
Most Recent Essential Thrombocythemia Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Top Treatments for Essential Thrombocythemia Clinical Trials
Treatment Name
Active Essential Thrombocythemia Clinical Trials
All Time Trials for Essential Thrombocythemia
First Recorded Essential Thrombocythemia Trial
IMG-7289
3
4
2017
Bomedemstat
1
1
2021
PXS-5505
1
1
2021
KRT-232
1
3
2019
Ropeginterferon alfa-2b
1
1
2020
Recently Completed Studies with FDA Approved Treatments for Essential Thrombocythemia
Treatment
Year
Sponsor
AVID200
2019
John Mascarenhas
IMG-7289
2017
Imago BioSciences,Inc.
Smac Mimetic LCL161
2014
M.D. Anderson Cancer Center

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 14th, 2021

Last Reviewed: October 23rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep;18(27):2999-3009. doi: 10.2217/fon-2022-0596. Epub 2022 Aug 4. Review. https://pubmed.ncbi.nlm.nih.gov/359245462 Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Aug 4. doi: 10.2217/fon-2022-0596. [Epub ahead of print] Review. https://pubmed.ncbi.nlm.nih.gov/359245463 Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, García-Gutiérrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 Nov 24;4(22):5825-5835. doi: 10.1182/bloodadvances.2020003314. https://pubmed.ncbi.nlm.nih.gov/33232476